Renal dysfunction and acceleration of coronary disease

被引：49

作者：

Yerkey, MW ^{[1
]}

Kernis, SJ ^{[1
]}

Franklin, BA ^{[1
]}

Sandberg, KR ^{[1
]}

McCullough, PA ^{[1
]}

机构：

[1] William Beaumont Hosp, Dept Med, Div Cardiol, Royal Oak, MI 48072 USA

来源：

HEART | 2004年 / 90卷 / 08期

关键词：

D O I：

10.1136/hrt.2003.015503

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：961 / 966

页数：6

共 20 条

[1] Biphasic effects of hemodialysis on platelet reactivity in patients with end-stage renal disease: A potential contributor to cardiovascular risk [J].

Aggarwal, A ;

Kabbani, SS ;

Rimmer, JM ;

Gennari, FJ ;

Taatjes, DJ ;

Sobel, BE ;

Schneider, DJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (02) :315-322

[2] Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction [J].

Beattie, JN ;

Soman, SS ;

Sandberg, KR ;

Yee, J ;

Borzak, S ;

Garg, M ;

McCullough, PA .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (06) :1191-1200

[3] The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions [J].

Best, PJM ;

Lennon, R ;

Ting, HH ;

Bell, MR ;

Rihal, CS ;

Holmes, DR ;

Berger, PB .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (07) :1113-1119

[4] Chronic kidney disease as a cardiovascular risk factor [J].

Best, PJM ;

Holmes, DR .

AMERICAN HEART JOURNAL, 2003, 145 (03) :383-386

[5] Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].

Boaz, M ;

Smetana, S ;

Weinstein, T ;

Matas, Z ;

Gafter, U ;

Iaina, A ;

Knecht, A ;

Weissgarten, Y ;

Brunner, D ;

Fainaru, M ;

Green, MS .

LANCET, 2000, 356 (9237) :1213-1218

[6] Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: A matched case-control study [J].

Bostom, AG ;

Shemin, D ;

Lapane, KL ;

Sutherland, P ;

Nadeau, MR ;

Wilson, PWF ;

Yoburn, D ;

Bausserman, L ;

Tofler, G ;

Jacques, PF ;

Selhub, J ;

Rosenberg, IH .

ATHEROSCLEROSIS, 1996, 125 (01) :91-101

[7] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].

Chertow, GM ;

Burke, SK ;

Raggi, P .

KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252

[8] Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].

Cheung, AK ;

Sarnak, MJ ;

Yan, GF ;

Dwyer, JT ;

Heyka, RJ ;

Rocco, MV ;

Teehan, BP ;

Levey, AS .

KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362

[9] SERUM LIPOPROTEIN(A) AND CORONARY-ARTERY DISEASE IN UREMIC PATIENTS ON CHRONIC-HEMODIALYSIS [J].

DOCCI, D ;

MANZONI, G ;

BILANCIONI, R ;

DELVECCHIO, C ;

CAPPONCINI, C ;

BALDRATI, L ;

NERI, L ;

FELETTI, C .

INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1994, 17 (01) :41-45

[10]

Foley RN, 1998, J AM SOC NEPHROL, V9, P267

← 1 2 →